Interactive Modeling for Ongoing Utility of Pharmacogenetic Diagnostic Testing: Application for Warfarin Therapy
Interactive Modeling for Ongoing Utility of Pharmacogenetic Diagnostic Testing: Application for Warfarin Therapy
Abstract Background: The application of pharmacogenetic results requires demonstrable correlations between a test result and an indicated specific course of action. We developed a computational decision-support tool that combines patient-specific genotype and phenotype information to provide strategic dosage guidance. This tool, through estimating quantitative and temporal parameters associated with the metabolism- and concentration-dependent response to warfarin, provides the necessary patient-specific context for interpreting international normalized ratio (INR) measurements. Methods: We analyzed clinical information, plasma S-warfarin concentration, and CYP2C9 (cytochrome P450, family 2, subfamily C, polypeptide 9) and VKORC1 (vitamin K epoxide reductase complex, subunit 1) genotypes for 137 patients with stable INRs. Plasma S-warfarin concentrations were evaluated by VKORC1 genotype (−1639G>A). The steady-state plasma S-warfarin concentration was calculated with CYP2C9 genotype–based clearance rates and compared with actual measurements. Results: The plasma S-warfarin concentration required to yield the target INR response is significantly (P < 0.05) associated with VKORC1 −1639G>A genotype (GG, 0.68 mg/L; AG, 0.48 mg/L; AA, 0.27 mg/L). Modeling of the plasma S-warfarin concentration according to CYP2C9 genotype predicted 58% of the variation in measured S-warfarin concentration: Measured [S-warfarin] = 0.67(Estimated [S-warfarin]) + 0.16 mg/L. Conclusions: The target interval of plasma S-warfarin concentration required to yield a therapeutic INR can be predicted from the VKORC1 genotype (pharmacodynamics), and the progressive changes in S-warfarin concentration after repeated daily dosing can be predicted from the CYP2C9 genotype (pharmacokinetics). Combining the application of multivariate equations for estimating the maintenance dose with genotype-guided pharmacokinetics/pharmacodynamics modeling provides a powerful tool for maximizing the value of CYP2C9 and VKORC1 test results for ongoing application to patient care.
- University of Mary United States
- University of California, Los Angeles United States
- University of Louisville United States
- Washington University in St. Louis United States
Adult, Aged, 80 and over, Male, Polymorphism, Genetic, Genotype, Anticoagulants, Middle Aged, Decision Support Techniques, Mixed Function Oxygenases, Phenotype, Pharmacogenetics, Vitamin K Epoxide Reductases, Humans, Female, Aryl Hydrocarbon Hydroxylases, International Normalized Ratio, Warfarin, Aged, Cytochrome P-450 CYP2C9
Adult, Aged, 80 and over, Male, Polymorphism, Genetic, Genotype, Anticoagulants, Middle Aged, Decision Support Techniques, Mixed Function Oxygenases, Phenotype, Pharmacogenetics, Vitamin K Epoxide Reductases, Humans, Female, Aryl Hydrocarbon Hydroxylases, International Normalized Ratio, Warfarin, Aged, Cytochrome P-450 CYP2C9
11 Research products, page 1 of 2
- 2010IsAmongTopNSimilarDocuments
- 2019IsAmongTopNSimilarDocuments
- 2012IsAmongTopNSimilarDocuments
- 2013IsAmongTopNSimilarDocuments
- 2010IsAmongTopNSimilarDocuments
chevron_left - 1
- 2
chevron_right
citations This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).38 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Average influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Top 10% impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Top 10%
